Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review)

RANZHIQIANG YANG1*, YINGHUI SONG1.2*, KASHIF SHAKoor1, WEIMIN YI1, CHUANG PENG1 and SULAI LIU1.2

1Department of Hepatobiliary Surgery and 2Central Laboratory, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005, P.R. China

Received November 10, 2021; Accepted February 22, 2022

DOI: 10.3892/mmr.2022.12687

Abstract. Intrahepatic cholangiocarcinoma (ICC) is a primary malignant liver tumour whose incidence is second only to that of hepatocellular carcinoma. ICC is a highly heterogeneous disease arising from neoplastic transformation of intrahepatic biliary epithelial cells (cholangiocytes), and it is characterized by a very poor prognosis. Signal transducer and activator of transcription 3 (STAT3) is an important oncogene that is widely expressed in numerous cancers. STAT3 is a candidate target for the treatment of ICC. However, studies on STAT3 and the occurrence and development of ICC require improvements. Therefore, the present review summarized the mechanism of STAT3 in ICC and provided a theoretical basis for STAT3 to become an effective target for determining the prognosis and treatment of ICC.

Contents
1. Introduction
2. Structure and function of STAT3
3. STAT3 signalling pathway is involved in the occurrence and development of intrahepatic cholangiocarcinoma
4. STAT3-related targets in intrahepatic cholangiocarcinoma
5. Summary and prospects

1. Introduction
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumour originating from the intrahepatic bile duct epithelium that accounts for ~10-15% of primary liver cancer cases (1,2), and its morbidity and mortality rates are increasing. At present, the molecular mechanism of ICC is not clear. Previous studies have shown that various cytokines produced during chronic inflammation cause abnormalities in oncogenes, DNA mismatch repair genes/proteins, and tumour suppressor genes. Genetic and epigenetic changes in cholangiocytes may promote proto-oncogene activation and tumour suppressor gene inactivation. These cumulative effects eventually lead to malignant transformation. In addition, cytokines also play important roles in promoting cell growth, inhibiting cell apoptosis, increasing cell invasiveness and promoting tumour angiogenesis (3,4). Currently, adjuvant treatments such as radiotherapy and chemotherapy have not significantly improved the overall survival (OS) rate of patients with ICC (5-7). Surgery is the only effective treatment for ICC. However, ICC is characterized by atypical clinical symptoms and early metastasis, leading to the diagnosis of advanced cancer and a lost opportunity for surgery. It is also prone to recurrence after surgery, and the overall 5-year survival rate after surgery is only 14-40% (6). With further research on the pathogenesis of ICC, an increasing number of molecular targets have been discovered. As the convergence point of numerous oncogenic signalling pathways, signal transducer and activator of transcription 3 (STAT3) plays a prominent role in regulating antitumour immune responses. In the tumour ecosystem, STAT3 is extensively overactivated in tumour cells to promote tumor growth. Moreover, STAT3 is also extensively overactivated in non-tumour cells to suppress the expression of key regulators of immune cell activation and promote the production of immunosuppressive factors (8). Therefore, drugs targeting the STAT3 signalling pathway have become a promising therapeutic strategy. Multiple studies (9-11) have shown that STAT3 expression is associated with several clinicopathological features, including tumour size, pathological satellites, vascular invasion, undifferentiated histology, lymph node metastasis and TNM stage. Patients with high STAT3 levels have a poor prognosis in terms of OS and disease-free survival (DFS). A multivariate survival analysis showed that
STAT3 was an independent prognostic factor for OS and DFS. Furthermore, it was observed that STAT3 overexpression promoted the invasion, metastasis and proliferation of ICC cells in vitro and in vivo and promoted STAT3 phosphorylation (12,13). STAT3 expression may become a new target for the treatment of patients with ICC.

2. Structure and function of STAT3.

STATs are DNA-binding proteins consisting of 750-850 amino acids, and their molecular weight is 84-113 kDa. STATs play a key role in cytokine signal transduction. The STAT family members expressed in mammalian cells mainly include STAT1, STAT2, STAT3, STAT4, STAT5 and STAT6, which are encoded by different genes. As one of the earliest discovered oncogenes, STAT3 has become an important gene that must not be ignored in tumour research and is involved in regulating cell proliferation, differentiation, apoptosis as well as other processes (14). STAT3 is a highly conserved protein consisting of ~770 amino acids (only one amino acid difference exists between mouse and human STAT3), that is expressed as three isoforms: STAT3 ‘alpha’, ‘beta’ and STAT3 gamma. It contains an amino terminal domain, a DNA binding domain and a C-terminal transcription activation domain. The amino terminal domain forms a coil structure. The structure of the DNA binding domain is an Src homology 2 (SH2) domain. The C-terminal domain adopts the transcription activation domain structure and is located between the two aforementioned domains. The SH2 domain plays an important role in signal transduction and specifically identifies phosphorylated tyrosine residues. It is activated by phosphorylation (15). The key tyrosine associated with dimer formation is located in the SH2 domain. STAT3 activity is regulated by the phosphorylation of serine 727, and phosphorylated STAT3 quickly enters the nucleus in the form of monomers. Homodimers or heterodimers of transcription factors are activated and interact with the promoters of their transcriptional target genes (Fig. 1). STAT3 is widely expressed in certain types of cells and tissues. STAT3 plays an indispensable role in early embryonic development and bone marrow cell differentiation in a STAT3-deficient mouse model (16). Under normal circumstances, STAT3, the main regulator that balances cell proliferation and apoptosis, participates in maintaining the growth and development of embryonic stem cells. Concurrently, it also participates in processes such as antigen tolerance. STAT3 activation is strictly regulated by a negative feedback mechanism, and it is inactivated and transported to the cytoplasm after transducing specific signals. However, upon stimulation with carcinogenic signals, STAT3 is continuously activated, exists in the nucleus in a constant activation state, and continuously activates target genes to promote tumour progression (17).

3. STAT3 signalling pathway is involved in the occurrence and development of ICC

Interleukin (IL)-6/Janus kinase (JAK)/STAT3 pathway. The JAK/STAT pathway is closely related to inflammatory factors. IL-6 binds to the soluble IL-6 receptor (SIL-6R) to activate the IL-6/JAK2/STAT3 signalling pathway (18). Briefly, SIL-6R recognizes and binds to IL-6 to form the SIL-6R/IL-6 complex, and activates glycoprotein 130 (GP130) on the surface of the cell membrane. Activated GP130 activates receptor tyrosine kinase and binds to the STAT3 protein, which phosphorylates and activates the nuclear transcription factor (19). STAT3 enters the nucleus and regulates the expression of inflammatory cytokines. The IL-6 family mainly includes IL-6, IL-11, ciliary neurotrophic factor, leukaemia inhibitory factor, oncostatin M (OSM), and cardiac trophic factor 1, cardiac trophic protein-like cytokine and cardiac trophic protein 2 (20). For example, IL-6 expressed in T cells, B cells or macrophages further promotes STAT3 phosphorylation and activation by activating JAK1, and STAT3 subsequently enters the nucleus to initiate downstream gene transcription (8), participating in the malignant process of ICC. Due to the continuous stimulation of upstream molecules, the abnormally and continuously activated IL-6/JAK/STAT3 pathway leads to resistance to apoptosis and further promotes tumour development. A study has shown that almost all cytokines in the IL-6 family activate the STAT3 protein. STAT3 is also considered the most important transcription factor mediating IL-6 function (8). Lipopolysaccharide (LPS) activates the IL-6/STAT3 signalling pathway in normal hepatic bile duct epithelial cells (21). LPS induces activation of the IL-6/STAT3 signalling pathway by not only activating this signalling pathway but also by increasing the expression of C-MYC and MCL-1, suggesting that the IL-6/STAT3 signalling pathway may be an important hub mediating inflammation and ICC (22). Both OSM and IL-11 are IL-6 family cytokines expressed in inflammatory and cancer processes. Tumour-associated neutrophils (TANs) and tumour-associated macrophages (TAMs) produce higher levels of OSM and IL-11 in coculture, respectively (23). Both of these cytokines activate the STAT3 signalling pathway in ICC cells. STAT3 knockout eliminates the tumour-promoting effects of TANs and TAMs on ICC, and increased levels of TANs and TAMs are related to the increased levels of p-STAT3 in tumour samples from patients with ICC (24). Researchers concluded that the effects of TANs and TAMs on ICC mainly depend on OSM- and IL-11-mediated activation of the STAT3 signalling pathway (Fig. 2).

IL-10/JAK/STAT3 pathway. IL-10 is a cytokine encoded by the IL-10 gene. In humans, IL-10 is produced mainly by immune cells, including monocytes, type 2 T helper cells and regulatory T cells (Tregs). IL-10 may play a role by regulating the JAK2/STAT3 signalling pathway and the extracellular signal-regulated kinase 1/2 pathway to alter the expression of downstream genes (25,26). The role of the JAK1/STAT3 pathway in tumours has attracted increasing attention. The JAK1/STAT3 pathway is an important pathway mediating cytokine signal transduction and is involved in various cell functions, such as differentiation, survival, proliferation and apoptosis, as well as pathological immune and inflammatory processes (27). According to previous studies (28,29), IL-10 induces STAT3 phosphorylation in Tregs. Although STAT3-deficient Tregs inhibit the proliferation of CD4+ T cells in vitro, their number in inflamed tissues is reduced, and their ability to inhibit the inflammatory activity of TH17 cells is also reduced (30). Thus, the mechanism by which IL-10 inhibits tumour-associated inflammation may be related to STAT3 phosphorylation and its downstream effects on cytokine
receptors or subsequent gene expression. After the successful polarization of M2 macrophages in vitro, IL-10 levels in the supernatant of M2 macrophages were significantly increased compared with untreated THP1 cells, and IL-10 was suggested to promote ICC cell migration, invasion and epithelial transformation via the STaT3 pathway (31) (Fig. 2).

**Epidermal growth factor receptor (EGFR) and STaT3 pathways.** EGFR, with a molecular weight of 170 kDa, is a member of the epidermal growth factor receptor family. EGFR is mainly located on the surface of human epithelial cells, fibroblasts, glial cells and other cells, and its signal transduction pathway plays an important role in promoting cell growth, differentiation, as well as other physiological processes. Loss of EGFR protein tyrosine kinase function or abnormal activity of key factors in related signalling pathways may lead to the development of tumours, immune deficiencies and cardiovascular diseases. Upon binding of the ligand to its extracellular ligand binding domain, EGFR is phosphorylated and forms either a homodimer or heterodimer, initiating an extensive intracellular signalling cascade (32-34). STaT3, one of the most important downstream effectors, is phosphorylated at Tyr705 by activated EGFR and is then translocated to the nucleus for transcriptional regulation, contributing to cell proliferation, resistance to apoptosis and angiogenesis (35,36). At present, EGFR overexpression or abnormal expression has been detected in various tumours, leading to the activation of downstream signalling pathways, particularly the continuous activation of STaT3 that causes its nuclear translocation and the transcription of downstream genes. Numerous in vitro and in vivo experiments have shown that the continuous expression and abnormal activation of the EGFR/STaT3 pathway are closely related to the occurrence and development of ICC (37). The overactivated EGFR/STaT3 signalling pathway is closely related to the development of ICC, based on an immunohistochemical analysis of ICC samples. EGFR/STaT3 overactivation promotes the growth of ICC cells (38,39) (Fig. 2).

Leucine-rich repeat containing G protein-coupled receptor 5 (LGR5) activates the STaT3 pathway. LGR5 is a member of the G protein-coupled receptor subfamily, also known as HG38 and GPR49. It is a large protein composed of 18 leucine-rich repeat units and 7 transmembrane regions. The structure of the protein is characterized by an extracellular region containing a signal peptide, 17 leucine-rich repeats and a highly conserved 7 α-helix transmembrane region (40). Previous studies (41-43) have detected increased expression of LGR5 in gastrointestinal, ovarian, liver, basal cell carcinoma and other tumour tissues to varying degrees (44). IKK kinase α upregulates the expression of LGR5 by activating the STaT3 signalling pathway and accelerates tumour progression in skin basal cell carcinoma cells (45). LGR5 is essential for Wnt signalling-induced activation of β-catenin, and by further activating STaT3, it enhances CSC-like features and the EMT, leading to aggressive tumour progression and a poor prognosis for patients with ICC (Fig. 2).

**FAP/STaT3/CCL2 pathway.** Fibroblast activation protein (FAP) is a membrane-bound glycoprotein that belongs to the serine protease family. It is a dimer composed of FAPα and β subunits with a molecular weight of 170 kDa (46). It has endopeptidase and weak dipeptidase activity, degrades a variety of dipeptides and type I collagen and is selectively expressed in cancer-associated fibroblasts (CAFs) of a variety of human solid tumours (47). FAP is expressed in embryonic cells, injured tissues and mesenchymal fibroblasts of >90% of malignant epithelial tumours, but it is rarely expressed in benign tumours and normal tissues; it is associated with extracellular matrix remodelling, tumour proliferation and metabolism (48,49).

A previous study showed that FAP induces inflammatory phenotypes and inflammation-related gene expression signatures in CAFs (50). Inducing the expression of FAP in normal fibroblasts produces an inflammatory phenotype similar to that of CAFs. In addition, FAP continuously activates STaT3 in fibroblasts in mouse liver tumour models, and CAFs are the main source of CCL2. STaT3-CCL2 signalling increases the recruitment of myeloid-derived suppressor cells (MDSCs) and thus promotes tumour growth from CAFs. Moreover, FAP, p-STaT3, and CCL2 levels are positively correlated with adverse pathological features of ICC, and increased FAP levels predict low survival rates. Recently, accumulating evidence has shown that CAFs participate in the progression of ICC by affecting tumour cells (51-54). Additionally, a previous study has shown that CAFs are the main source of CCL2 in the ICC microenvironment (55). In addition, the tumorigenic function of FAP mediated by CCL2 in ICC depends on its intracellular activation of STaT3 signalling in CAFs. FAP recruits MDSCs in a CCL2-dependent manner in ICC. In addition to mediating immunosuppression, MDSCs promote tumour progression by enhancing angiogenesis through a paracrine pathway, suggesting that approaches specifically targeting CAFs may be a more effective and safer treatment strategy for ICC (Fig. 2).

4. **STaT3-related targets in ICC**

Approximately 70% of malignant tumours present abnormally increased STaT3 activity, including acute myeloid leukaemia,
multiple myeloma, bladder, breast and colon cancer and ICC (56-64). Phosphorylated STAT3 levels have been revealed to be associated with poor clinical outcomes in patients with these cancers. Therefore, extensive effort has been devoted to identifying and developing STAT3 inhibitors for cancer treatment. However, given the wide range of intracellular functions of STAT3, possible inhibitors have been difficult to develop. However, numerous phase I, phase II, and even phase III trials of drugs targeting STAT3 have been conducted. A number of these treatments are only used as research tools due to their shortcomings, such as limited bio-absorption, utilization, drug resistance, and poor stability, but other drugs achieve favourable effects through oral bio-absorption and by binding to the STAT3 SH2 domain (65-68). Numerous nonpeptide SH2 domain inhibitors have also been identified and shown to inhibit STAT3 activity, including STAT-21, IL-6, STAT, Tic, c188-9, oPB31121/51602, WP1066, S3i-201, BP-1-102, STX-0119 and HJc0123 (69-76). The application of these agents in ICC requires further confirmation. In addition to the function of STAT3 inhibitors, another method to inhibit STAT3 activity is to inhibit the interaction of STAT3 with target gene promoter elements. AZD9150 is the second generation of previous iterations optimized by merger, 2', 4' constraints of ethyl STAT3 antisense oligonucleotide-modified residues, which have been shown to prevent STAT3 from binding DNA in a variety of tumours after intravenous injections to inhibit tumour growth (77-83) (Fig. 3). AZD9150 is expected to achieve favourable efficacy in ICC treatment.

5. Summary and prospects

According to previous studies, tumour proliferation, invasion and metastasis, angiogenesis, drug resistance and prognosis are all related to tobacco, alcohol, diet, stress, infection, and chronic inflammation (84,85). Inflammatory factors such as intrahepatic bile duct stones with chronic cholangitis, a high incidence of viral hepatitis B, and biliary parasite infection are considered high-risk factors for ICC (86). STAT3 is located at the intersection of multiple oncogenic signalling pathways and is abnormally activated in malignant tumour tissues, including ICC. STAT3 is mainly activated by various kinases through phosphorylation (87). Activated STAT3 transduces signals from various cytokines and growth factors into the nucleus and participates in regulating the transcription of corresponding target genes, thereby participating in modulating cell survival, proliferation, angiogenesis as well as other processes (88). This inflammatory cascade activates STAT3, leading to the overproduction of bile duct epithelium growth factor, thus
promoting CCA initiation. Due to the role of STAT3 in inflammation and cancer development, targeting STAT3 is a rational treatment strategy for ICC. Numerous studies have shown that STAT3 activation is closely related to the prognosis of patients with multiple myeloma, gastric cancer, hepatocellular carcinoma, lung and laryngeal cancer and ICC (89-92). STAT3 is associated with the development of malignant tumours mainly through STAT3-mediated expression of key target genes that regulate cell proliferation, apoptosis inhibition and the hypoxia response (93). Activated STAT3 also induces the expression of VEGF, which promotes invasive and metastatic angiogenesis (94). In addition, STAT3 binds to the IL-6 promoter, creating a positive feedback loop that leads to increased IL-6 expression. VEGF and IL-6 also exert immunosuppressive effects that may promote the immune escape of tumour cells following STAT3 overactivation, thus forming a vicious cycle of the occurrence, metastasis, and invasion of ICC (95).

STAT3 is often used as an important indicator to distinguish ICC from extrahepatic cholangiocarcinoma. Studies (96-98) have shown significantly higher STAT3 expression in ICC than in extrahepatic cholangiocarcinoma. Downregulated STAT3 expression was revealed to significantly reduce the proliferation of ICC cell lines, such as RBE and ICC-9810 cells, and significantly increase the apoptotic rate of RBE and ICC-9810 cells. However, when STAT3 expression was upregulated, the opposite results were obtained. STAT3 promoted the proliferation and inhibited the apoptosis of intrahepatic bile duct cancer cells (99).

STAT3 expression and activation are currently known to be regulated by various mechanisms. Certain cytokines and growth factors activate STAT3 by binding to specific receptors and participate in the pathophysiological process of diseases. Under physiological conditions, STAT3 activation is rapid and transient, lasting only minutes to hours. In the tumour microenvironment, dysregulation of growth factors, cytokines, and co-stimulators leads to continued phosphorylation of STAT3 tyrosine residues. Excessive or constitutive activation of STAT3 alters cell proliferation and apoptosis, promotes invasion and metastasis, and exacerbates immunosuppression in the microenvironment, directly affecting the prognosis and quality of life of patients (100).

Considering the important association between the high STAT3 expression and the malignancy and prognosis of ICC, STAT3 is expected to become a molecular marker for clinical disease staging and may become a new therapeutic target. Based on certain preclinical studies that have identified the potential therapeutic effects of drugs targeting the STAT signal transduction pathway, the development of highly effective and well-tolerated drugs is anticipated in the future. The molecular mechanism of ICC requires further exploration (101), which will facilitate the application of specific genes and signalling pathways to the classification of ICC molecular subtypes and the development of targeted therapeutic drugs. Further studies are required to take advantage of multidisciplinary comprehensive treatment, including surgery, chemotherapy and targeted therapy.
according to the molecular characteristics of ICC in order to improve the quality of life and prolong the survival time of patients.

Acknowledgements
Not applicable.

Funding
The present study was supported by grants from the following organizations: The Hunan Provincial Natural Science Foundation of China (grant no. 2020JJ5610), the Hunan Natural Science Fund for Excellent Young Scholars (grant no. 2021JJ20003), the Youth Talent of Hunan (grant no. 2020RC3066), the China Postdoctoral Science Foundation (grant no. 2020M68115/2021T140197) and the Natural Science Foundation of Changsha (grant no. kq2007023/kq2004115).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
RY and YS contributed to the analysis and manuscript preparation. KS revised the review. CP, WY and SL contributed to the conception of the study. YS and SL helped perform the analysis and participated in constructive discussions. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Razumilava N and Gores GJ: Cholangiocarcinoma. Lancet 383: 2168-2179, 2014.
2. Saha SK, Zhu AX, Fuchs CS and Brooks GA: Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise. Oncologist 21: 594-599, 2016.
3. Cucchielli A, Cappelli A, Mosconi C, Zhong JH, Cescon M, Pinna AD and Golﬁeri R: Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: A meta-regression study. Liver Int 37: 1056-1064, 2017.
4. Yang XW, Yuan JM, Chen JY, Yang J, Gao QG, Yan XZ, Zhang BH, Feng S and Wu MC: The prognostic importance of jaundice in surgical resection with curative intent for gallbladder cancer. BMC Cancer 14: 652, 2014.
5. Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER and Denlinger CS: Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer 122: 1349-1369, 2016.
6. Ben-Menachem T: Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol 19: 615-617, 2007.
7. Yang XW, Li L, Hou GJ, Yan XZ, Xu QG, Chen L, Zhang BH and Shen F: STAT3 overexpression promotes metastasis in cholangiocarcinoma and correlates negatively with surgical outcome. Oncotarget 8: 7710-7721, 2017.
8. Yu H, Lee H, Herrmann A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer 14: 736-746, 2014.
9. Yang S, Shen Y, Wang S, Shen Q and Zhou X: The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett 415: 117-128, 2018.
10. To SQ, Dmello RS, Richards AK, Ernst M and Chand AL: STAT3 signaling in breast cancer: Multicellular actions and therapeutic potential. Cancers (Basel) 14: 429, 2022.
11. Yu H, Kortylewski M and Pardoll D: Crosstalk between STaT3 and cancer immunity: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41-51, 2007.
12. Mohassab AM, Hassan HA, Abdelhamid D, Gouda AM, Youssif BGM, Tateishi H, Fujita M, Otsuka M and Abdel-Aziz M: STAT3 transcription factor as target for anti-cancer therapy. Pharmacol Rep 72: 1101-1124, 2020.
13. Zimmers TA, Fishel ML and Bonetto A: STAT3 in the systemic inflammation of cancer cachexia. Semin Cell Dev Biol 54: 28-41, 2016.
14. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an oncogene. Cell 98: 295-303, 1999.
15. Jin LL, Wybenga-Groot LE, Tong J, Taylor P, Minden MD, Trudel S, McGlade CJ and Moran MF: Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity. Mol Cell Proteomics 14: 695-706, 2015.
16. Gutiérrrez M: Activating mutations of STAT3: Impact on human growth. Mol Cell Endocrinol 518: 110979, 2020.
17. Wang SW and Sun YM: The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol 44: 1032-1040, 2014.
18. Montero P, Milara J, Roger I and Cortijo J: Role of Jak/Stat signaling in interstitial lung diseases: Molecular and cellular mechanisms. Int J Mol Sci 22: 6211, 2021.
19. Banerjee S, Biehl A, Gadina M, Hasni S and Schwartz DM: JAK-STAT Signaling as a target for inflammatory and autoimmune diseases: Current and future prospects. Drugs 77: 521-546, 2017.
20. Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Ma H, Wei D and Sun S: The role of Jak/Stat signaling pathway and its inhibitors in diseases. Int Immunopharmacol 80: 106210, 2020.
21. Yokoyama T, Komori A, Nakamura M, Takii Y, Kamihira T, Shimoda S, Mori T, Fujiwara S, Koyabu M, Taniguchi K, et al: Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int 26: 467-476, 2006.
22. Bode JG, Ehlting C and Häussinger D: The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal 24: 1185-1194, 2012.
23. Zhou Z, Wang P, Sun R, Li J, Hu Z, Xin H, Luo C, Zhou J, Fan J and Zhou S: Tumor-associated neutrophils and macrophages interplay contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. J Immunother Cancer 9: e001946, 2021.
24. Shaul ME and Fridlender ZG: Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol 16: 601-620, 2019.
25. Tam YY and Chi H: Bipolar/red-shaped microglia are proliferating microglia with distinct M1/M2 phenotypes. Sci Rep 4: 7279, 2014.
26. Leticia P, Font-Nieves M, Van den Haute C, Baekelandt V, Planas AM and Pozas E: IL-10 regulates adult neurogenesis by modulating ERK and STAT3 activity, Front Cell Neurosci 9: 57, 2015.
27. Wu X, Pan T, Quan Z, Li J, Yu Z, Wang X, Li J, Li C, Yan M, Zhu Z, et al: IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget 8: 20741-20750, 2017.
28. Ju JH, Heo YJ, Cho ML, Jhun JY, Park JS, Lee SY, Oh HJ, Moon SJ, Kwok SK, Park KS, et al: Modulation of STAT3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proliferation of Treg cells. Arthritis Rheum 64: 3543-3552, 2012.
29. Wang XQ, Hu GH, Kou W, Shen Y, Kang HY and Hong SL: Reciprocal roles of STAT3 and STAT5 in nasal polyposis. Am J Otolaryngol 33: 741-752, 2012.
30. Zheng Y, Wang Z, Deng L, Zhang G, Yuan X, Huang L, Xu W and Shen L: Modulation of STAT3 and STAT5 activity rectifies the imbalance of Th17 and Treg cells in patients with acute coronary syndrome. Clin Immunol 157: 65-77, 2015.

31. Yuan H, Lin Z, Liu Y, Jiang Y, Liu K, Tu M, Yao N, Qu C and Hong J: Intrahepatic cholangiocarcinoma induced M2-polarized Tumor-associated macrophages facilitate tumor growth and invasiveness. Cancer Cell Int 20: 586, 2020.

32. Gao Y, Chen J, ZHU Z Y, et al: Research progress of EGFR gene mutation and its detection methods. Mol Diag Ther 3: 51-57, 2011.

33. Roskoski Jr R: ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Pharmacol Res 87: 42-59, 2014.

34. Bi WW, Zhang WH, Yin GH, Luo H, Wang SQ, Wang H, Li H, Zhang Y, Nie DZ, Chen X: indoleamine 2-3 dioxygenase (IDO) and EGFR co-expression in breast cancer tissue by immunohistochemistry. Asian Pac J Cancer Prev 15: 5535-5538, 2014.

35. Zhao X, Sun X and Li XL: Expression and clinical significance of STAT3, p-STAT3, and VEGF-C in small cell lung cancer. Asian Pac J Cancer Prev 13: 2873-2877, 2012.

36. Fang B: Genetic Interactions of STAT3 and Anticancer Drug Development. Cancers (Basel) 6: 493-524, 2015.

37. Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S and DiGiovanni J: Epidermal growth factor receptor-mediated activation of STAT3 during multistage skin carcinogenesis. Cancer Res 64: 2382-2389, 2004.

38. Zhang C, Xu H, Zhou Z, T'an Y, Cao X, Cheng G and Liu Q: Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intracellular cholangiocarcinoma. Exp Cell Res 345: 4995-5003, 2016.

39. Zhang F, Li L, Yang X, Wang B, Zhao J, Lu S and Yu X: Expression and activation of EGFR and STAT3 during the multistage carcinogenesis of intrahepatic cholangiocarcinoma induced by 3-methyl-4-dimethylaminoazobenzene in rats. Mol Med Rep 5: 788-792, 2012.

40. Kumar KK, Burgess AW and Gulbis JM: Structure and function of LGR5: An enigmatic G-protein coupled receptor marking stem cells. Protein Sci 23: 551-565, 2014.

41. Katoh M and Katoh M: Wnt signaling in stem cell biology and regenerative medicine. Curr Drug Targets 9: 565-570, 2008.

42. Katoh M and Katoh M: Stat3 activation is associated with bladder cancer cell invasion and survival. Mol Med Rep 8: 52-58, 2013.

43. Sonnenblick A, Shriki A, Galun E, Axelrod JH, Daum H, Rottebery Y, Hamburger T, Mall B and Peretz T: Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (STAT3) is a marker of good prognosis. Clin Transl Oncol 14: 232-236, 2012.

44. Schaefer LR, Ken Z, Fuller GN and Schaefer TS: Constitutive activation of Stat3alpha in brain tumors: Localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 21: 2098-2065, 2002.

45. Takemoto S, Ushijima K, Kawanou T, Yamauchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Iijichi M, Kakuma T, et al: Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br J Cancer 106: 967-972, 2009.

46. Zhang HF, Chen Y, Wu C, Wu ZY, Twardy DJ, Alshareef A, Liao LD, Xue YJ, Wu YA, Chen B, et al: The opposing function of STAT3 as an oncogene and tumor suppressor is dictated by the expression status of STAT3β in esophageal squamous cell carcinoma. Clin Cancer Res 22: 691-703, 2016.

47. Geiger JL, Grandis JR and Bauml J: The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol 56: 84-92, 2016.

48. Li S, Priceman SJ, Xiu H, Zhang W, Deng J, Liu Y, Huang J, Zhu W, Chen M, Hu W, et al: icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS One 8: e81657, 2013.

49. Wang Y, Qu A and Wang H: Signal transducer and activator of transcription 4 in liver diseases. Int J Biol Sci 11: 448-455, 2015.

50. Suh YA, Jo SY, Lee HY and Lee C: Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells. Int J Oncol 46: 1405-1411, 2015.

51. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Hauru E, Laudano A, Sebti S, Hamilton AD and Jove R: Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 276: 45443-45455, 2001.

52. Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Hauru E, Sebti S, Hamilton AD and Jove R: Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 3: 261-269, 2004.

53. Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, Kaluvarachki KK, Chen X, Bast RC Jr, Liao WS and McMurray JS: Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem 54: 5349-5363, 2011.

54. Azzenne EJ, Klostergaard J, Mandal PK, Liao WS, Lu Z, Gao F, Bast RC Jr, McMurray F and McMurray JS: A phosphopeptide mimetic prodrg targeting the SH2 domain of STAT3 inhibits tumor growth and angiogenesis. J Exp Ther Oncol 15: 155-162, 2012.
Hayakawa F, Sugimoto K, Harada Y, Hashimoto N, Ohi N, Kurahashi S and Naoe T: A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. J Biol Chem 286:1366, 2013.

Kim MJ, Nam HJ, Kim HP, Han SW, Im SA, Kim TY, Oh DY and Bang YJ: OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 335: 145-152, 2014.

Bendell JC, Hong DS, Burris HA III, Naing A, Jones SF, Falchuk G, Bricmont P, Elekes A, Rock EP and Kurzer K: Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol 74: 125-130, 2014.

Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, Heo DS, Yuasa M, Yanagihara Y and Bang YJ: Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors. Cancer Res Treat 47: 607-615, 2015.

Okusaka T, Ueno H, Ikeda M, Mitsuhasha S, Ishii H, Yokosuka O, Ooka Y, Yoshimoto Y, Yanagihara Y and Okita K: Phase I and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with refractory solid malignancies. Ann Oncol 26: 998-1005, 2015.

Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Bharadwaj U, Eckols TK, Xu X, Kasembeli MM, Chen Y, Shen J, Li and G: inhibitory effects of decoy-odn targeting Sun Z, Yao Z, Liu S, Tang H and Yan X: an oligonucleotide Zhang X, Liu P, Zhang B, Mao H, Shen L and Ma Y: inhibitory effects of STaT3 decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunology 211: 199-209, 2006.

Zhang X, Zhang J, Wang L, Wei H and Tian Z: Therapeutic effects of STAT3 decoy oligodeoxyribonucleotide on human lung cancer in xenograft mice. BMC Cancer 7: 149, 2007.

Zhang X, Liu F, Zhang B, Yao H, Shen L and Ma Y: Inhibitory effects of STAT3 decoy oligodeoxyribonucleotides on human epithelial ovarian cancer cell growth in vivo. Int J Mol Med 32: 623-628, 2013.

Chan KS, Sano S, Ikuchi K, Anders J, Komazawa N, Takeda J and DiGiovanni J: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 114: 720-728, 2004.

Zhang Q, Hossain DM, Duttagupta P, Moreira D, Zhao X, Won H, Buettner R, Nechaev S, Majka M, Zhang B, et al: Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood 127: 1687-1700, 2016.

Sun XJ, Jiang TH, Zhang XP and Mao AW: Role of the tumor microenvironment in pancreatic adenocarcinoma. Front Biosci (Landmark Ed) 21: 31-41, 2016.

Eggert T and Greten TF: Tumor regulation of the tissue environment in the liver. Pharmacol Ther 173: 47-57, 2017.

Peng NF, Li LQ, Qin X, Guo Y, Peng T, Xiao KY, Chen XG, Yang YF, Su ZX, Chen B, et al: Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: A possible role of hepatitis B virus. Ann Surg Oncol 18: 1258-1266, 2011.

Jarnicki A, Putoczki T and M美容T: STAT3: Linking inflammation to epithelial cancer-more than a ‘gut’ feeling? Cell Div 5: 14, 2010.

Liu Y, Liao S, Bennett S, Tang H, Song D, Wood D, Zhan X and Xu J: STAT3 and its targeting inhibitors in osteosarcoma. Cell Prolif 54: e12974, 2021.

Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vaidyan S, Estrov Z, Talpaz M and Aggarwal BB: Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103: 3175-3184, 2004.

Kanda N, Seno H, Konda Y, Murasawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, et al: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23: 4921-4929, 2004.

Haura EB, Zheng Z, Song L, Cantor A and Bepler G: Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11: 8288-8294, 2005.

Liu B, Ren Z, Shi Y, Guan C, Pan Z and Zong Z: Activation of signal transducers and activators of transcription 3 and overexpression of its target gene CyclinD1 in laryngeal carcinomas. Laryngoscope 118: 1976-1980, 2008.

Bournazou E and Bromberg J: Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT2: e23828, 2013.

Yu H and Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004.

Schmidt-Arras D and Rose-John S: IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol 64: 1403-1415, 2016.

Liu Z, Zhang M, Li Y, Zhang Y and She Z: Effect of small interfering RNA targeting p63 on the proliferation and invasiveness of human cholangiocarcinoma cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 32: 207-210, 2012 (In Chinese).

Sia D, Tovar V, Moenici A and Llovet JM: Intrahepatic cholangiocarcinoma: Pathogenesis and rationale for molecular therapies. Oncogene 32: 4861-4870, 2013.

Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabré R, Pinoy R, Torrez-Martín M, Bassaganya L, Moenici A, Peix J, et al: Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol 73: 315-327, 2020.

Liu S, Xiu P, Liu N, et al: Effects of STAT3 on proliferation and apoptosis of human intrahepatic bile duct carcinoma cells. Shandong Med J 55: 5-7, 2015 (In Chinese).

Dong J, Cheng XD, Zhang WD and Qin JJ: Recent update on development of Small-Molecule STAT3 inhibitors for cancer therapy: From phosphorylation inhibition to protein degradation. J Med Chem 64: 8884-8915, 2021.

Tang Y, Tang Z, Yang J, Liu T and Tang Y: MicroRNA-7-5p Inhibits Migration, Invasion and Metastasis of Intrahepatic Cholangiocarcinoma by Inhibiting MyD88. J Clin Transl Hepatol 9: 809-817, 2021.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.